develop
effect
safe
vaccin
requir
detail
understand
virolog
immunolog
characterist
infect
viru
abil
mutat
quickli
result
great
viral
divers
make
develop
effect
vaccin
challeng
therefor
mani
research
group
vaccin
field
pursu
develop
vaccin
induc
broadli
neutral
antibodi
bnab
ie
antibodi
target
function
envelop
glycoprotein
env
mani
differ
viru
isol
focu
vaccin
design
gener
solubl
env
trimer
mimet
induc
antibodi
much
progress
made
last
year
gener
recombin
env
trimer
resembl
nativ
env
spike
requir
negat
inher
instabl
flexibl
nativ
env
trimer
accomplish
molecular
design
result
solubl
stabl
env
trimer
trimer
prototyp
clade
trimer
gold
standard
hiv
nativelik
trimer
immunogen
design
allow
determin
highresolut
structur
env
trimer
recent
structur
membranederiv
jrfl
trimer
confirm
solubl
stabil
trimer
resembl
nativ
env
trimer
present
viral
membran
moreov
design
could
extrapol
isol
therebi
expand
toolkit
vaccin
design
use
immunogen
anim
trial
protein
variou
strain
elicit
autolog
strainspecif
neutral
antibodi
nab
howev
immunogen
fail
elicit
potent
bnab
anim
describ
sever
approach
pursu
order
increas
perform
solubl
env
trimer
mimet
immunogen
induc
nab
first
review
differ
method
use
improv
stabil
env
trimer
includ
forc
viral
evolut
structurebas
design
high
throughput
screen
mutant
trimer
select
improv
trimer
mammalian
cell
display
also
review
epitop
env
trimer
mimet
target
immun
system
assess
differ
immun
strategi
env
trimer
immunogen
employ
includ
cocktail
sequenti
vaccin
regimen
nativ
env
trimer
unstabl
flexibl
conform
heterogen
appli
earli
gener
solubl
env
trimer
deriv
consequ
took
mani
year
elucid
highresolut
structur
xray
crystallographi
cryoelectron
microscopi
em
techniqu
initi
low
resolut
cryoelectron
tomographi
reconstruct
membranebound
solubl
trimer
provid
new
insight
highresolut
structur
trimer
solv
use
wide
assort
potent
bnab
becam
avail
last
decad
larg
gain
resolut
obtain
first
env
trimer
crystal
structur
resolut
includ
complex
trimer
bnab
first
cryoem
deriv
model
trimer
complex
bind
site
bnab
resolut
addit
provid
lattic
contact
facilit
crystal
featur
facilit
em
reconstruct
bnab
also
provid
valid
structur
respect
bnab
epitop
clearli
present
next
step
improv
resolut
trimer
structur
complex
trimer
combin
sever
new
bnab
use
bnab
direct
interfac
antibodi
increas
resolut
provid
new
detail
prefus
conform
especi
partial
disord
region
sosip
platform
appli
trimer
differ
clade
structur
complex
divers
bnab
also
elucid
provid
valuabl
new
inform
structurebas
vaccin
design
overal
structur
sosip
trimer
show
highli
similar
trimer
core
reveal
differ
variabl
loop
eman
core
anoth
breakthrough
came
elucid
cryoem
structur
membranederiv
jrfl
trimer
stabil
bnab
sosip
mutat
overal
structur
featur
membranederiv
trimer
well
bnab
epitop
agre
well
solubl
sosip
trimer
howev
subtl
differ
observ
region
substitut
solubl
trimer
break
helix
present
fulllength
env
structur
exactli
meant
high
similar
membranederiv
solubl
version
env
confirm
valu
sosip
design
gener
solubl
env
spike
mimet
modif
sosip
design
involv
introduct
flexibl
glyser
linker
replac
furin
cleavag
site
sometim
addit
modif
effect
result
singl
chain
trimer
requir
furin
cleavag
strategi
stabil
env
trimer
understand
exploit
stabil
viru
protect
env
nab
viru
evolv
darwinian
way
select
mutat
env
particular
variabl
loop
mask
protein
surfac
shift
glycan
shield
viru
evolut
also
exploit
lab
obtain
valuabl
inform
mutat
stabil
env
trimer
retain
function
mutat
use
stabil
recombin
env
vaccin
candid
cultur
viru
harsh
condit
unphysiolog
temperatur
increment
concentr
denatur
guhcl
leaman
colleagu
identifi
stabl
env
mutant
contain
seven
mutat
compar
wildtyp
counterpart
mutat
locat
interfac
includ
posit
fig
tabl
substitut
also
identifi
earlier
studi
sequenc
earli
gener
rel
stabl
sosip
protein
compar
unstabl
jrfl
sosip
de
taey
et
al
introduc
present
mutat
distinct
clade
b
clade
c
trimer
order
increas
trimer
stabil
substitut
improv
nativelik
trimer
select
base
studi
viru
becom
depend
entri
inhibitor
adapt
cold
substitut
locat
domain
fig
tabl
like
keep
viru
prefus
conform
imped
step
toward
conform
interact
region
thu
mutat
increas
stabil
nativ
env
spike
virion
also
use
develop
stabl
solubl
nativelik
env
immunogen
sosip
trimer
base
viru
isol
initi
form
stabl
nativelik
trimer
effici
howev
avail
trimer
structur
provid
suffici
structur
detail
design
modif
improv
structur
stabil
env
trimer
allow
gener
stabl
trimer
mani
differ
isol
clade
consid
stabil
vaccin
antigen
much
learnt
natur
extremophil
bacteria
archea
thrive
extrem
environment
condit
high
low
temperatur
respect
alkalin
acid
condit
ph
ph
respect
evolv
highli
stabl
protein
compar
mesophil
homologu
extremophil
organ
natur
evolut
appli
six
method
protein
stabil
sever
method
appli
either
intent
env
trimer
vaccin
design
first
thermophil
protein
often
increas
number
hydrophob
residu
domain
oligom
interfac
facilit
tighter
pack
protein
domain
similar
strategi
appli
env
trimer
stabil
trimer
prevent
exposur
nonnab
exampl
de
taey
et
al
avoid
spontan
exposur
loop
increas
hydrophob
interact
within
domain
domain
introduc
two
leu
residu
loop
fig
tabl
similarli
chuang
et
al
kulp
et
al
steichen
et
al
rutten
et
al
introduc
hydrophob
mutat
trimer
core
trimer
stem
use
structurebas
design
mammalian
cell
display
result
increas
env
pack
reduc
flexibl
fig
tabl
second
extremophil
protein
contain
higher
number
aromat
amino
acid
enhanc
protein
thermost
ring
stack
interact
well
hydrophob
pack
structurebas
immunogen
design
sever
group
use
principl
introduc
aromat
residu
reduc
exposur
increas
stabil
trimer
apex
trimer
base
trimer
interfac
interfac
interfac
fig
tabl
overal
introduct
hydrophob
aromat
residu
account
total
number
mutat
describ
literatur
increas
env
trimer
stabil
third
protein
thermophil
organ
tend
increas
number
charg
residu
involv
intern
ion
pair
hydrogen
bond
well
increas
number
posit
charg
residu
solventexpos
surfac
provid
stabil
surfac
env
trimer
introduct
charg
amino
acid
interfac
also
contribut
format
wellord
nativelik
trimer
differ
clade
enhanc
thermost
fig
tabl
fourth
protein
thermophil
organ
usual
contain
mani
predict
disulfid
bond
mesophil
organ
increas
protein
stabil
dramat
mesophil
protein
mani
disulfid
bond
rare
consequ
strong
posit
correl
number
disulfid
bond
protein
maximum
growth
temperatur
thermophil
organ
virus
influenza
vaccinia
virus
contain
disulfid
bond
link
two
env
subunit
togeth
env
natur
disulfid
bond
result
shed
subunit
first
step
gener
stabl
nativelik
trimer
therefor
introduct
disulfid
bond
subunit
fig
tabl
stabil
flexibl
trimer
interfac
addit
disulfid
bond
introduc
env
trimer
intersubunit
disulfid
bond
interprotom
disulfid
bond
fig
tabl
furthermor
intrasubunit
disulfid
bond
describ
kwon
et
al
guenaga
et
al
also
stabil
trimer
prefus
state
fig
tabl
combin
three
nonn
disulfid
bond
result
hyperst
trimer
reach
melt
temperatur
respect
fifth
thermophil
organ
increas
number
prolin
glycin
residu
loop
provid
conform
rigid
protein
hiv
field
similar
approach
use
gener
solubl
env
trimer
sinc
region
form
helix
postfus
state
adopt
partial
disord
conform
prefus
state
introduc
mutat
loop
destabil
postfus
state
stabil
prefus
state
similarli
introduct
glycin
prolin
residu
stabil
solubl
env
trimer
fig
tabl
kong
et
al
comput
model
loop
low
gibb
free
energi
result
increas
number
prolin
residu
rigidif
loop
last
mechan
thermophil
organ
appli
surviv
high
temperatur
reduct
asparagin
glutamin
residu
prevent
deamid
strategi
intent
use
hiv
vaccin
design
yet
thu
strategi
stabil
env
trimer
isol
use
high
throughput
screen
select
mammalian
display
structurebas
design
mani
way
mirror
extremophil
achiev
natur
surviv
extrem
condit
result
improv
stabil
solubl
env
trimer
allow
us
use
immunogen
immunogen
studi
facilit
gener
toolkit
trimer
differ
clade
sever
trimer
evalu
immunogen
studi
suggest
case
increas
thermost
translat
increas
immunogen
furthermor
increas
trimer
shelf
life
avoid
cold
chain
transport
storag
help
eventu
produc
vaccin
global
avail
nativelik
env
trimer
test
immunogen
small
anim
mostli
rabbit
nonhuman
primat
studi
indic
nativelik
trimer
consist
induc
first
time
nab
respons
hardtoneutr
tier
primari
isol
howev
heterolog
primari
isol
weakli
sporad
neutral
highli
stabl
nativelik
trimer
design
improv
immunogen
trimer
increas
halflif
vivo
thu
present
bnab
epitop
immunogen
studi
highli
stabl
trimer
increas
gener
autolog
nab
respons
induc
weak
heterolog
tier
respons
case
trimer
thermost
vitro
use
paramet
link
vivo
observ
also
import
investig
addit
stabil
paramet
trimer
stabil
serum
immun
sosip
trimer
also
induc
strong
nonneutr
antibodi
nonnab
respons
epitop
neoepitop
bottom
trimer
heterolog
primari
isol
weakli
sporad
neutral
point
possibl
direct
research
improv
nativelik
trimer
immunogen
first
recent
shown
nab
respons
anim
immun
sosip
trimer
domin
specif
target
hole
glycan
shield
specif
peptid
surfac
surround
amino
acid
posit
viru
isol
nlink
glycan
autolog
nab
respons
might
case
start
point
gener
bnab
respons
could
also
distract
compet
respons
latter
scenario
true
one
might
want
dampen
immunodomin
isolatespecif
glycanhol
direct
nab
respons
one
strategi
counteract
immunogen
specif
glycan
hole
would
immun
trimer
contain
glycan
posit
previou
studi
shown
immun
trimer
base
isol
denser
glycan
shield
induc
broader
heterolog
nab
respons
compar
trimer
isol
larg
hole
glycan
shield
support
pursuit
strategi
second
immun
trimer
induc
strong
respons
nonnab
epitop
lead
hypothesi
immunodomin
interf
gener
bnab
respons
rabbit
immun
improv
version
trimer
trimer
contain
mutat
sequest
epitop
sosip
trimer
induc
weaker
respons
tier
viru
nab
respons
without
affect
autolog
nab
respons
next
iter
trimer
design
two
addit
hydrophob
residu
incorpor
loop
trimer
complet
abolish
respons
loop
although
modif
reduc
immunogen
improv
autolog
nab
respons
result
broaden
nab
respons
similar
result
recent
obtain
kulp
et
al
use
differ
design
third
gener
solubl
env
trimer
result
exposur
neoepitop
bottom
trimer
occlud
viral
membran
env
trimer
present
virion
suggest
bottom
trimer
present
anoth
immunodomin
nonnab
epitop
could
interfer
nab
respons
j
van
gil
c
cottrel
b
ward
r
w
sander
unpublish
data
prevent
exposur
epitop
one
could
hide
exampl
place
trimer
nanoparticl
although
interfer
trimer
bottom
nonnab
respons
attract
hypothesi
formal
proof
yet
nonnab
respons
interfer
desir
nab
bnab
repons
howev
trimer
bottom
nonnab
epitop
usual
sole
peptid
natur
b
cell
recogn
epitop
much
frequent
b
cell
repertoir
probabl
higher
affin
b
cell
recogn
composit
peptideglycan
bnab
epitop
higher
affin
b
cell
might
select
advantag
lower
affin
b
cell
target
bnab
epitop
might
bind
process
antigen
consequ
receiv
cell
help
make
unlik
b
cell
intrins
capac
matur
bnab
thrive
environ
favor
b
cell
target
nonnab
strainspecif
glycan
hole
nab
epitop
howev
argument
somewhat
theoret
context
immun
respons
rais
env
trimer
anim
human
vaccin
experi
dissect
detail
address
concern
improv
understand
fate
env
trimer
vivo
number
studi
focus
germin
center
respons
env
trimer
macaqu
immun
stabl
env
trimer
germin
center
cell
lymph
node
collect
time
use
fine
needl
aspir
fna
therebi
avoid
need
take
lymph
node
biopsi
therebi
blunt
respons
lymph
node
macaqu
gener
immun
respons
trimer
nab
respons
correl
quantit
gc
b
cell
frequenc
studi
provid
frameofrefer
studi
germin
center
b
cell
tfh
cell
role
epitop
immunodomin
subdomin
furthermor
insight
amount
env
enter
lymph
node
halflif
env
protein
circul
would
help
effort
studi
immunogen
deliv
b
cell
improv
previou
work
immunogen
includ
suggest
worthwhil
exploit
fluoresc
tag
nativelik
trimer
answer
question
especi
whether
highli
stabl
trimer
show
longer
trimer
half
life
presenc
serum
proteas
monoval
immun
solubl
env
trimer
induc
strong
nab
respons
autolog
virus
weak
sporad
heterolog
tier
nab
respons
one
strategi
increas
neutral
breadth
involv
explor
differ
vaccin
regimen
cocktail
differ
immunogen
highli
divers
pathogen
influenza
viru
influenza
viru
use
annual
updat
vaccin
compos
trival
tetraval
cocktail
differ
inactiv
influenza
virus
howev
annual
influenza
vaccin
protect
viral
variant
close
relat
vaccin
strain
exemplifi
difficult
induc
bnab
respons
highli
divers
virus
search
univers
flu
vaccin
share
similar
search
bnabinduc
vaccin
increas
neutral
breadth
explor
use
cocktail
sequenti
regimen
observ
immun
combin
immunogen
cocktail
formul
sequenc
induc
bnab
mere
autolog
nab
respons
furthermor
autolog
nab
respons
promin
immundomin
trimer
cocktail
thu
immun
respons
show
narrow
specif
similar
report
influenza
vaccin
result
indic
env
vaccin
base
cocktail
sequenc
randomli
chosen
trimer
unlik
induc
bnab
altern
cocktail
sequenti
formul
could
guid
b
cell
lineag
toward
bnab
activ
ration
design
sinc
natur
infect
bnab
develop
coevolut
viru
antibodi
one
strategi
pursu
immun
longitudin
env
sequenc
patient
develop
bnab
respons
strategi
aim
recapitul
evolutionari
path
viru
assum
develop
bnab
respons
larg
depend
viral
characterist
anoth
somewhat
relat
strategi
term
germlinetarget
focus
activ
rare
subset
b
cell
express
b
cell
receptor
germlin
precursor
intrins
capac
develop
bnab
sosip
trimer
gener
bind
infer
germlin
version
bnab
sever
group
design
immunogen
bind
specif
germlin
antibodi
guid
b
cell
respons
toward
develop
broadli
neutral
antibodi
trimer
also
use
boost
respons
prime
epitopespecif
immunogen
exampl
xu
et
al
appli
trimer
immun
regimen
aim
focus
immun
respons
fusion
peptid
immun
guinea
pig
macaqu
fusion
peptid
coupl
carrier
protein
klh
boost
respons
stabil
sosip
trimer
immun
strategi
induc
autolog
nab
respons
anim
substanti
nab
respons
heterolog
virus
anim
isol
antibodi
respons
broad
neutral
could
confirm
antibodi
target
fusion
peptid
autolog
heterolog
virus
anoth
strategi
overcom
low
affin
immunogen
desir
rare
germlin
precursor
bnab
multimer
antigen
therebi
increas
potenc
ab
respons
crosslink
b
cell
receptor
use
liposom
ferritin
nanocag
present
env
trimer
surfac
inde
improv
nab
respons
flexibl
nanoparticl
system
would
allow
incorpor
trimer
differ
clade
lineag
enhanc
nab
respons
conserv
b
cell
epitop
describ
make
stabl
env
trimer
structur
immunolog
studi
use
quest
vaccin
howev
lesson
learnt
field
also
appli
virus
vice
versa
similar
env
viral
fusion
protein
respiratori
syncyti
viru
rsv
f
protein
intrins
metast
easili
switch
prefus
postfus
form
lot
effort
invest
produc
stabl
solubl
env
trimer
influenza
ha
protein
compar
stabl
easili
express
contrast
rsv
f
protein
similarli
hiv
env
quit
unstabl
adopt
postfus
conform
purifi
solubl
protein
mclellan
colleagu
introduc
disulfid
bond
hydrophob
residu
keep
rsv
glycoprotein
prefus
state
krarup
et
al
prevent
transit
protein
postfus
state
introduc
helixbreak
prolin
refold
region
quit
similar
done
env
recent
highresolut
structur
viral
glycoprotein
solv
includ
human
parainfluenza
viru
ebola
viru
lassa
viru
human
betacoronaviru
lymphocyt
choriomening
viru
herp
simplex
viru
sever
fever
thrombocytopenia
syndrom
viru
abovement
strategi
work
env
also
benefit
stabil
nativelik
prefus
form
sever
glycoprotein
keep
middl
east
respiratori
syndrom
coronaviru
merscov
glycoprotein
prefus
state
pallesen
et
al
introduc
two
prolin
start
central
helix
protein
similarli
substitut
introduc
env
trimer
similarli
retain
lassa
viru
glycoprotein
prefus
conform
hasti
colleagu
incorpor
prolin
domain
improv
stabil
author
introduc
disulfid
bond
two
subunit
improv
cleavag
site
previous
done
env
trimer
thu
gener
strategi
retain
viral
glycoprotein
prefus
conform
structurebas
design
improv
immunogen
env
trimer
also
learn
recombin
vaccin
viral
pathogen
current
avail
hepat
b
viru
hepat
e
viru
human
papillomaviru
use
recombin
viruslik
particl
immunogen
vaccin
selfassembl
nanoparticl
mimic
nativ
virion
expos
neutral
epitop
surfac
previous
discuss
improv
nanoparticl
design
vaccin
field
pursu
sever
group
includ
us
short
strategi
use
improv
immunogen
design
provid
templat
design
vaccin
candid
virus
vice
versa
review
latest
design
strategi
stabil
solubl
env
trimer
well
differ
immun
strategi
maxim
valu
develop
nativelik
trimer
immunogen
avail
highresolut
structur
design
differ
immun
strategi
promis
germlinetarget
nanoparticl
present
combin
increas
understand
host
immunolog
respons
env
trimer
advanc
field
trimer
vaccinolog
effort
advanc
field
provid
lesson
subunit
vaccin
virus
divers
issu
limit
influenza
viru
dengu
viru
hepat
c
viru
